{"schema_version":"secwatch.filing_event.v1","accession":"0001485003-23-000068","form_type":"8-K","ticker":"CARM","cik":"0001485003","company_name":"Carisma Therapeutics Inc.","filed_at":"2023-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.198790+00:00","generated_at":"2026-06-18T23:27:17.729574+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Sesen Bio gets Nasdaq exception to complete Carisma merger by March 10; delisting risk if not compliant","bullets":["Nasdaq Panel granted exception from $1.00 bid price rule to complete merger with Carisma by March 10, 2023.","Special meeting of stockholders on March 2, 2023 to approve merger and reverse stock split.","If compliance not demonstrated by March 10, common stock will be delisted unless further exception granted.","Company must demonstrate compliance with all initial listing requirements upon closing of merger."],"urls":{"canonical":"https://secwatch.observer/filing/0001485003-23-000068","json":"https://secwatch.observer/filing/0001485003-23-000068.json","markdown":"https://secwatch.observer/filing/0001485003-23-000068.md","text":"https://secwatch.observer/filing/0001485003-23-000068.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1485003/000148500323000068/0001485003-23-000068-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1485003/000148500323000068/sesn-20230224.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T23:27:17.729574+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}